Return to site
Return to site

InBrain Pharma Secures €1.8 Million in Funding for the PERCEPAR Project under France 2030’s “First Factory” Initiative to Industrialize Anaerobic Dopamine Production for Parkinson’s Disease

InBrain Pharma, a clinical stage biotech specialized in therapeutic solution development against neurodegenerative diseases, is thrilled to announce that it has been selected as a winner of the “First Factory” call for projects operated by Bpifrance on behalf of the French State, as part of the France 2030 plan. The funding supports its PERCEPAR project (PERfusion CErébrale de dopamine, a therapeutic innovation for PARkinson’s patients), which aims to industrialize the manufacturing process of anaerobic dopamine (A-dopamine). More information

PreviousNext
Cookie Use
We use cookies to improve browsing experience, security, and data collection. By accepting, you agree to the use of cookies for advertising and analytics. You can change your cookie settings at any time. Learn More
Accept all
Settings
Decline All
Cookie Settings
Necessary Cookies
These cookies enable core functionality such as security, network management, and accessibility. These cookies can’t be switched off.
Analytics Cookies
These cookies help us better understand how visitors interact with our website and help us discover errors.
Preferences Cookies
These cookies allow the website to remember choices you've made to provide enhanced functionality and personalization.
Save